Genocea Biosciences Inc (GNCAQ)

[INFINITI]

Leerink Partners Thinks Genocea Biosciences’ Stock is Going to Recover

Source: TipRanks
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Genocea Biosciences (GNCA – Research Report) yesterday. The company's shares closed last Monday at $0.60, close to its 52-week low of $0.39. According to TipRanks.com, Graybosch 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.6% and a 31.9% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $5.68, implying an 890.8% upside from current levels. In a report issued on April 10, Robert W.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-genocea-biosciences-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral